Potent inhibitors of MYST3, a histone acetyltransferase
- Detailed Technology Description
- A series of novel and potent inhibitors of MYST3 or monocytic leukaemia zinc finger gene (MOZ), a histone acetyltransferase, with potential application in the treatment of cancers.
- *Abstract
-
A series of novel and potent inhibitors of MYST3 or monocytic leukaemia zinc finger gene (MOZ), a histone acetyltransferase, with potential application in the treatment of cancers.
1. Potent (low nanomolar) small molecule inhibitors of MYST3, a transcription coregulatory and epigenetic drug target.
2. Demonstrated mechanism-based cellular activity.
3. In vivo studies underway in lymphoma and solid tumour models
Monash is seeking a license partner to co-develop its advance lead series of MYST3 inhibitors through preclinical development and nomination of a clinical candidate, to evaluation in clinical trials.
- Country/Region
- USA
For more information, please click Here
